Abstract
Yeni nesil oral antikoagülanlar, K vitamini antagonistlerinin dezavantajlarına alternatif olarak geliştirilmişlerdir. Günümüzde yeni nesil oral antikoagülanlar, non-valvuler atrial fibrilasyonda inmenin önlenmesinde, total kalça ve diz protezi sonrası derin ven trombozunun önlenmesinde ve tromboemboli tedavisinde kullanılmaktadır. Biz bu makalede yeni nesil oral antikoagülanların özelliklerini ve kullanım alanlarını, laboratuvar izlemini, antidotlarını ve girişimsel işlemlerde hastaların yönetimini gözden geçirdik.
References
- Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association, American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107 (12): 1692-711.
- Trikha R, Kowey PR. Practical considerations for the nonvitamin K antagonist oral anticoagulants. Cardiology 2017; 136 (2): 115-24.
- Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 2018; 15 (5): 273-81.
- Reddy ST, Cossey TC, Savitz SI, Grotta JC. Non-vitamin K oral anticoagulants (NOACs) and their reversal. Curr Neurol Neurosci Rep 2017; 17: 67.
- Barnes GD, Kurtz B. Direct oral anticoagulants: unique properties and practical approaches to management. Heart 2016; 102 (20): 1620-6.
- Verdecchia P, Angeli F, Aita A, Bartolini C, Reboldi G. Why switch from warfarin to NOACs? Intern Emerg Med 2016; 11 (3): 289-93.
- Abed HS, Kilborn MJ, Chen V, Sy RW. Reversal Agents in the Era of NOACs. J Atr Fibrillation 2017; 10 (4): 1634.
- Milling TJ Jr, Ziebell CM. A review of reversal of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. Trends Cardiovasc Med 2019. pii: S1050-1738 (19) 30041-6.
- Amin A. Choosing non-vitamin K antagonist oral anticoagulants: Practical considerations we need to know. Ochsner J 2016;16 (4): 531-41.
- Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 2018; 135: 60-79.
- Arias Pou P, González A, Martínez LJP, Latorre AD, Alonso MS. Periprocedural management of patients receiving novel oral anticoagulants. Eur J Hosp Pharm 2018; 25 (6): 292-7.
Abstract
Novel oral anticoagulants have been developed as an alternative to the disadvantages of vitamin K antagonists. Nowadays, novel oral anticoagulants are indicated in stroke prevention in patients with nonvalvular atrial fibrillation, prevention of venous thromboembolism after hip or knee replacement surgery and treatment of venous thromboembolism. We review properties of novel oral anticoagulants, indications, recommendations for their laboratory monitoring, reversal agents, and periprocedural management of patients.
References
- Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association, American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107 (12): 1692-711.
- Trikha R, Kowey PR. Practical considerations for the nonvitamin K antagonist oral anticoagulants. Cardiology 2017; 136 (2): 115-24.
- Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 2018; 15 (5): 273-81.
- Reddy ST, Cossey TC, Savitz SI, Grotta JC. Non-vitamin K oral anticoagulants (NOACs) and their reversal. Curr Neurol Neurosci Rep 2017; 17: 67.
- Barnes GD, Kurtz B. Direct oral anticoagulants: unique properties and practical approaches to management. Heart 2016; 102 (20): 1620-6.
- Verdecchia P, Angeli F, Aita A, Bartolini C, Reboldi G. Why switch from warfarin to NOACs? Intern Emerg Med 2016; 11 (3): 289-93.
- Abed HS, Kilborn MJ, Chen V, Sy RW. Reversal Agents in the Era of NOACs. J Atr Fibrillation 2017; 10 (4): 1634.
- Milling TJ Jr, Ziebell CM. A review of reversal of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. Trends Cardiovasc Med 2019. pii: S1050-1738 (19) 30041-6.
- Amin A. Choosing non-vitamin K antagonist oral anticoagulants: Practical considerations we need to know. Ochsner J 2016;16 (4): 531-41.
- Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 2018; 135: 60-79.
- Arias Pou P, González A, Martínez LJP, Latorre AD, Alonso MS. Periprocedural management of patients receiving novel oral anticoagulants. Eur J Hosp Pharm 2018; 25 (6): 292-7.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Case Reports |
| Authors | |
| Publication Date | January 20, 2021 |
| Submission Date | April 6, 2020 |
| Published in Issue | Year 2021Volume: 60 Suppl:1 (Rheumatology) |
